{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:16:35Z","timestamp":1773314195082,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We investigated whether the treatment needs of patients with dementia with Lewy bodies (DLB) and their caregivers, along with their attending physicians\u2019 perception of those treatment needs, differ according to the clinical department visited by the patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a subanalysis of a multicenter, cross-sectional, observational survey study. Data from the main study were classified according to the clinical department visited by the patient: psychiatric group (P-group), geriatric internal medicine group (G-group), and neurology group (N-group). The treatment needs of patients and caregivers were defined as \u201cthe symptom that causes them the most distress\u201d, and the frequency of each answer was tabulated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This subanalysis included 134, 65, and 49 patient\u2013caregiver pairs in the P-, G-, and N-groups, respectively. Statistically significant differences in patient background characteristics such as patient age; initial symptom domains; use of cholinesterase inhibitors, levodopa, antipsychotics, and Yokukansan; and total scores of the Mini-Mental State Examination, Neuropsychiatric Inventory-12, and Movement Disorder Society-Unified Parkinson\u2019s Disease Rating Scale Parts II and III were shown among the three subgroups. While there were no differences in patients\u2019 treatment needs among the subgroups, residual analysis showed that in the N-group, parkinsonism was more of a problem than other symptom domains (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). There were significant differences in caregivers\u2019 treatment needs among the three subgroups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The patient\u2013physician concordance rates for the symptom domains that caused patients the most distress were: P-group, 42.9% (kappa coefficient [\u03ba]\u2009=\u20090.264); G-group, 33.3% (\u03ba\u2009=\u20090.135), and N-group, 67.6% (\u03ba\u2009=\u20090.484). The caregiver\u2013physician concordance rates for the symptom domains that caused the caregivers the most distress were: P-group, 54.8% (\u03ba\u2009=\u20090.351), G-group, 50.0% (\u03ba\u2009=\u20090.244), and N-group, 47.4% (\u03ba\u2009=\u20090.170).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This subanalysis revealed differences in the treatment needs of patients with DLB and their caregivers according to the clinical department they attended. There might be a lack of awareness of those treatment needs by the attending physicians, regardless of their specialty.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>UMIN Clinical Trials Registry UMIN000041844.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-024-01419-6","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T03:12:15Z","timestamp":1710385935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Differences in the treatment needs of patients with dementia with Lewy bodies and their caregivers and differences in their physicians\u2019 awareness of those treatment needs according to the clinical department visited by the patients: a subanalysis of an observational survey study"],"prefix":"10.1186","volume":"16","author":[{"given":"Manabu","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Toya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Yamakage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"1419_CR1","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1186\/s12877-021-02540-z","volume":"21","author":"N Nakahori","year":"2021","unstructured":"Nakahori N, Sekine M, Yamada M, Tatsuse T, Kido H, Suzuki M. Future projections of the prevalence of dementia in Japan: results from the Toyama Dementia Survey. BMC Geriatr. 2021;21:602.","journal-title":"BMC Geriatr"},{"key":"1419_CR2","doi-asserted-by":"crossref","unstructured":"2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17:327-406.","DOI":"10.1002\/alz.12328"},{"key":"1419_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheimer\u2019s disease: epidemiology and clinical progression. Neurol Ther. 2022;11:553\u201369.","journal-title":"Neurol Ther"},{"key":"1419_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"1419_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/psyg.12005","volume":"13","author":"H Fujishiro","year":"2013","unstructured":"Fujishiro H, Iseki E, Nakamura S, Kasanuki K, Chiba Y, Ota K, et al. Dementia with Lewy bodies: early diagnostic challenges. Psychogeriatr. 2013;13:128\u201338.","journal-title":"Psychogeriatr"},{"key":"1419_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/psyg.12408","volume":"19","author":"Y Manabe","year":"2019","unstructured":"Manabe Y, Odawara T, Konishi O. Fact-finding survey on diagnostic procedures and therapeutic interventions for parkinsonism accompanying dementia with Lewy bodies. Psychogeriatrics. 2019;19:345\u201354.","journal-title":"Psychogeriatrics"},{"key":"1419_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/psyg.12399","volume":"19","author":"T Odawara","year":"2019","unstructured":"Odawara T, Manabe Y, Konishi O. A survey of doctors on diagnosis and treatment of dementia with Lewy bodies: examination and treatment of behavioural and psychological symptoms. Psychogeriatrics. 2019;19:310\u20139.","journal-title":"Psychogeriatrics"},{"key":"1419_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13195-022-01130-4","volume":"14","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto M, Manabe Y, Yamaguchi T, Toya S, Ikeda M. Treatment needs of dementia with Lewy bodies according to patients, caregivers, and physicians: a cross-sectional, observational, questionnaire-based survey in Japan. Alzheimers Res Ther. 2022;14:188.","journal-title":"Alzheimers Res Ther"},{"key":"1419_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"M Folstein","year":"1975","unstructured":"Folstein M, Folstein S, McHugh P. \u201cMini-Mental State\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"1419_CR10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129\u201370.","journal-title":"Mov Disord"},{"key":"1419_CR11","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","volume":"48","author":"JL Cummings","year":"1997","unstructured":"Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10-16.","journal-title":"Neurology"},{"key":"1419_CR12","first-page":"175","volume":"66","author":"M Hashimoto","year":"2014","unstructured":"Hashimoto M, Manabe Y, Mori E, Hirono N, Kosaka K, Ikeda M. Content validity inter-rater reliability of the Cognitive Fluctuation Inventory. Brain Nerve. 2014;66:175\u201383 [in Japanese].","journal-title":"Brain Nerve"},{"key":"1419_CR13","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/geront\/20.6.649","volume":"20","author":"SH Zarit","year":"1980","unstructured":"Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist. 1980;20:649\u201355.","journal-title":"Gerontologist"},{"key":"1419_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/0891988704267463","volume":"17","author":"D Aarsland","year":"2004","unstructured":"Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson\u2019s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17:164\u201371.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1419_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbr.2005.02.019","volume":"161","author":"T Teaktong","year":"2005","unstructured":"Teaktong T, Piggott MA, Mckeith IG, Perry RH, Ballard CG, Perry EK. Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behav Brain Res. 2005;161:299\u2013305.","journal-title":"Behav Brain Res"},{"key":"1419_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.23557","volume":"72","author":"E Mori","year":"2012","unstructured":"Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial. Ann Neurol. 2012;72:41\u201352.","journal-title":"Ann Neurol"},{"key":"1419_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","volume":"7","author":"M Ikeda","year":"2015","unstructured":"Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7:4.","journal-title":"Alzheimers Res Ther"},{"key":"1419_CR18","doi-asserted-by":"publisher","first-page":"104474","DOI":"10.1016\/j.archger.2021.104474","volume":"96","author":"CS Chu","year":"2021","unstructured":"Chu CS, Yang FC, Tseng PT, Stubbs B, Dag A, Carvalho AF, et al. Treatment efficacy and acceptability of pharmacotherapies for dementia with lewy bodies: a systematic review and network meta-analysis. Arch Gerontol Geriatr. 2021;96:104474.","journal-title":"Arch Gerontol Geriatr"},{"key":"1419_CR19","doi-asserted-by":"publisher","first-page":"e1031","DOI":"10.1212\/WNL.0000000000012450","volume":"97","author":"E Matar","year":"2021","unstructured":"Matar E, White SR, Taylor JP, Thomas A, McKeith IG, Kane JPM, et al. Progression of clinical features in lewy body dementia can be detected over 6 months. Neurology. 2021;97:e1031\u201340.","journal-title":"Neurology"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01419-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01419-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01419-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T03:12:58Z","timestamp":1710385978000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01419-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1419"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01419-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"After approval by the Observational Study Ethics Committee of Osaka University Hospital (IRB No., 20171\u20134, November 11, 2020), this study was conducted in compliance with the ethical principles of the Declaration of Helsinki (revised in 2013), the Ethical Guidelines for Medical and Health Research Involving Human Subjects (partially revised in 2017), and the research protocol. This study was registered in the UMIN Clinical Trials Registry under the identifier number UMIN000041844. Written informed consent was obtained from all patients and their caregivers. Physicians consented to participate in this study via the web.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MI has received research funding from Sumitomo Pharma Co., Ltd. ST is an employee of Sumitomo Pharma Co., Ltd. YM has received research funding and travel expenses from Sumitomo Pharma Co., Ltd. HY is an employee of 3H Medi Solution Inc. MH has received travel expenses from Sumitomo Pharma Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}